Skip to main
VTRS

Viatris (VTRS) Stock Forecast & Price Target

Viatris (VTRS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Viatris is positioned for strong future growth with its extensive portfolio of legacy products and focus on key therapeutic areas. The company's merger with Upjohn and Mylan has solidified its position as one of the largest generic drug manufacturers in the world, with a strong presence in over 165 countries. Despite potential challenges and risks in the industry, Viatris's development of innovative drugs and potential for future growth make it a promising investment opportunity for analysts.

Bears say

Viatris is heavily reliant on the success of its new drugs, cenerimod and selatogrel, for future growth. However, the potential higher risk associated with these drugs, combined with a lack of a biosimilars vertical, make the company's strategy and its stock unappealing to financial analysts. While Viatris does have a diversified portfolio, with a strong focus on generics and biosimilars, its legacy products only make up 60% of sales and may not be enough to drive a richer multiple for the company's shares. Financial analysts have a neutral outlook on Viatris, noting its inexpensive valuation at an EV/2027E EBITDA of ~7x, but remaining cautious due to the unknown outcomes of the new drugs and lack of potential for a biosimilars vertical.

Viatris (VTRS) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viatris and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viatris (VTRS) Forecast

Analysts have given Viatris (VTRS) a Buy based on their latest research and market trends.

According to 7 analysts, Viatris (VTRS) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viatris (VTRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.